CCHW.NE - Columbia Care Inc.

NEO - NEO Real Time Price. Currency in CAD
5.40
-0.10 (-1.82%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close5.40
Open5.46
Bid5.34 x N/A
Ask5.42 x N/A
Day's Range5.38 - 5.48
52 Week Range5.38 - 5.48
Volume7,570
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.21
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Columbia Care to Participate in Upcoming September Conferences

    Columbia Care Inc. , one of the largest fully integrated operators in the global medical cannabis industry w

  • Business Wire

    Columbia Care and Moeller Pharma GmbH Enter into Exclusive Agreement to Develop Portfolio of Proprietary, Plant-Based Combination Cannabinoid Functional Health and Wellness Products

    Columbia Care Inc. (CCHW.NE) (OTCQX:CCHWF) (FSE:3LP) (“Columbia Care” or the “Company”), one of the largest fully integrated operators in the global medical cannabis industry with licenses across the US and EU, announced that it has entered into an exclusive agreement with Moeller Pharma GmbH (“Moeller”), a GMP-certified German producer of high-quality herbal extracts, functional beverages and plant-derived combination supplements for the pharmaceutical and food industries, to develop a portfolio of proprietary cannabinoid-infused products to be sold globally, beginning with Europe and the US.

  • Business Wire

    Columbia Care Announces Collaboration with IPS Specials and Grow Biotech to Import BeneCeed™ Tablets to the United Kingdom for Clinical Study

    Columbia Care Inc. (CCHW.NE) (OTCQX:CCHWF) (FSE:3LP) (“Columbia Care” or the “Company”), one of the largest fully integrated operators in the global medical cannabis industry with licenses across the US and EU, announced today a collaboration with IPS Specials, an experienced compounding pharmaceutical manufacturer, importer and distributor of unlicensed “specials” and licensed medicines in the UK and the rest of the EU, and Grow Biotech, a company bridging the gap between existing cannabis medicines and accepted pharmaceutical standards, to import Columbia Care’s proprietary, broad-spectrum high-cannabidiol (CBD) BeneCeed tablets as a potential investigational medicinal product (IMP) to the United Kingdom (UK) for clinical study. Pending approval by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), BeneCeed would be examined in a late-stage Phase 2b clinical trial and, to the Company’s knowledge, become the first botanical cannabinoid IMP approved for import from the US and the first product from Columbia Care’s proprietary portfolio of cannabis-based products to be studied in randomized clinical trials.

  • Business Wire

    Columbia Care Completes Consolidation of Minority Interest in Illinois Operations

    Columbia Care Inc. (CCHW.NE) (OTCQX:CCHWF) (FSE:3LP) (“Columbia Care” or the “Company”), one of the largest fully integrated operators in the global medical cannabis industry with licenses across the US and EU, announced today that it has completed its acquisition of the remaining 25% minority interest in its Illinois operation which is now consolidated 100% under its wholly owned Columbia Care Illinois subsidiary.

  • Business Wire

    Columbia Care Reports Second Quarter 2019 Results

    Second quarter 2019 revenue of $19.3 million, an increase of 102% over prior year period

  • Benzinga

    Columbia Care Inc To Trade In US On The OTCQX Market

    OTC Market Group announced Monday cannabis company Columbia Care Inc. (NEO:CCHW) (OTCQX: COLXF) will start trading on the OTCQX Best Market. Columbia Care is one of the biggest multi-sate operators in the medical cannabis industry, with licenses in 15 jurisdictions over the US and the EU. OTC Market Group operates three markets for 10,000 U.S. and global securities.

  • Business Wire

    Columbia Care Enters World’s Largest Regulated Cannabis Market with Grand Opening of Flagship Dispensary in San Diego, California

    Columbia Care Inc. (“Columbia Care”, or the “Company”) (NEO: CCHW, OTC: COLXF), one of the largest fully-integrated operators in the global medical cannabis industry with licenses in 15 jurisdictions across the US and the EU, today announced the launch of its west coast expansion strategy with the grand opening of its flagship San Diego dispensary, the Company’s first facility in California. Strategically located in the heart of San Diego’s Pacific Beach neighborhood at 4645 DeSoto Street, Columbia Care California will provide convenient access to its portfolio of high-quality, cannabis-based health and wellness solutions to more than 3.3 million local residents and more than 35 million tourists that visit the region annually.

  • Business Wire

    Columbia Care Announces Launch of Pioneering Research Study to Identify Genetic Factors Affecting the Efficacy and Safety of Medical Cannabis

    Columbia Care Inc. (“Columbia Care” or the “Company”) (NEO: CCHW, OTC: COLXF), one of the largest global operators in the medical cannabis industry, with licenses in 15 jurisdictions in the US and the EU, today announced the initiation of a research study designed to optimize the use of Columbia Care’s precisely-manufactured, pharmaceutical-quality medical cannabis products through the identification of genetic factors affecting their safety and efficacy. Rosemary Mazanet, M.D, Ph.D., Chief Scientific Officer of Columbia Care, and Carlos D. Bustamante, Ph.D., Professor of Biomedical Data Science at Stanford University, President of CDB Consulting Ltd. and Columbia Care Scientific Advisory Board Member will lead the visionary study, which will enroll patients in New York State who are currently taking Columbia Care’s proprietary, precisely-formulated, full-spectrum medical cannabis products.

  • Business Wire

    Columbia Care Announces National Launch of the CNC Card – the Nation’s First Cannabis Industry Credit Card

    First legal, transparent and highly scalable credit card solution available to fast-growing $23B US cannabis industry. Columbia Care Inc. (NEO:CCHW, OTC:COLXF) (“Columbia Care” or the “Company”), one of the largest multistate operators in the medical cannabis industry, with licenses in 15 jurisdictions in the US and the EU, today announced that it is launching its Columbia National Credit program (the “CNC Card”) across the United States, following a successful pilot program in New York.

  • Business Wire

    Columbia Care and Westmed Announce Initiation of a Research Study on the Safety and Efficacy of Precisely Formulated Cannabis-Based Medicines in Rheumatologic Patients

    Columbia Care Inc. (“Columbia Care”, or the “Company”) (CCHW.NE), one of the largest multi-state operators in the medical cannabis industry, with licenses in 15 jurisdictions in the US and the EU, and Westmed Medical Group (‘Westmed’), an award-winning multispecialty medical practice staffed by a team of 500 top physicians and advanced care providers, today announced the initiation of a collaborative study examining the therapeutic effectiveness and safety of medical cannabis as a pain reliever in rheumatologic patients with inflammatory arthritis. The research will be led by Dr. Jill Landis, M.D., board certified rheumatologist at Westmed.

  • Business Wire

    Columbia Care Reports First Quarter 2019, Fourth Quarter and Full Year 2018 Financial Results

    NEW YORK-- -- First quarter 2019 revenue increase of 45% over prior year Completion of go-public transaction provides capital to fund long-term growth prospects Expansion of US footprint with 13 lease signings in Florida, dispensary openings in Brooklyn, NY and San Diego, CA, reinforcing organic growth strategy in key markets Columbia Care Inc. , one of the largest multi-state operators in the medical ...

  • Business Wire

    Columbia Care Launches “100,000,000 Ways to Break the Opioid Crisis” Initiative

    Columbia Care Inc. (“Columbia Care”, or the “Company”) (CCHW.NE), a leading international medical cannabis company, today announced the launch of its new initiative, “100,000,000 Ways to Break the Opioid Crisis,” a nationwide effort to test whether precisely-formulated medical cannabis can be a safe and effective alternative to opioids for pain. Columbia Care is kicking off the “100,000,000 Ways to Break the Opioid Crisis” initiative by providing its precisely-formulated pharmaceutical-quality cannabis-based medicines for a precedent-setting study to determine whether medical cannabis can reduce participants’ dependence on opioid use in managing pain.

  • Business Wire

    Columbia Care Releases Preliminary Results for First Quarter 2019 and Full Year 2018

    Organic growth continues to drive revenue increases of 45% for Q1 2019 and 35% for FY 2018 on year-over-year basis

  • Medicare-for-all could ‘dramatically’ increase access to medical cannabis
    Yahoo Finance Video

    Medicare-for-all could ‘dramatically’ increase access to medical cannabis

    Key Democrats have been talking up Medicare-for-all in the presidential race, and Nicholas Vita, the CEO of cannabis company Columbia Care, says a move to that type of health care system could benefit medical cannabis too. He spoke to Yahoo Finance’s Brian Sozzi and Akiko Fujita.